Abstract:TLRs are a class of pattern recognition receptors (PRRs) that detect invading microbes by recognizing pathogen‐associated molecular patterns (PAMPs). Upon PAMP engagement, TLRs activate a signaling cascade that leads to the production of inflammatory mediators. The localization of TLRs, either on the plasma membrane or in the endolysosomal compartment, has been considered to be a fundamental aspect to determine to which ligands the receptors bind, and which transduction pathways are induced. However, new observations have challenged this view by identifying complex trafficking events that occur upon TLR‐ligand binding. These findings have highlighted the central role that endocytosis and receptor trafficking play in the regulation of the innate immune response. Here, we review the TLR4 and TLR9 transduction pathways and the importance of their different subcellular localization during the inflammatory response. Finally, we discuss the implications of TLR9 subcellular localization in autoimmunity. The innate immune system uses pattern‐recognition receptors (PRRs) to sense the presence of invading microbes. PRRs recognize endogenous and exogenous ligands, including pathogen‐associated molecular patterns (PAMPs), which are conserved chemical motifs expressed by microorganisms. According to the model proposed by Janeway, the recognition of PAMPs by PRRs is the primary strategy for self‐ versus nonself‐discrimination. 1 Antigen‐presenting cells express high levels of PRRs that, upon ligand binding, transduce an intracellular signal, leading to the production of several factors involved in the initiation of the immune response. Ultimately, these events induce the activation of adaptive immunity and the formation of memory cells. 2 Dysregulation of PRR‐mediated responses may compromise immunologic self‐tolerance. For example, aberrant activation triggered by host‐derived nucleic acids causes autoimmune disorders, such as Sjögren's syndrome (SS), 3 systemic lupus erythematosus (SLE), 4 multiple sclerosis (MS), 5 systemic sclerosis (SSc), 6 rheumatoid arthritis (RA), 7 and psoriasis. 8 PRRs are classified into 5 families: TLRs, C‐type lectin receptors (CTLs), NOD‐like receptors (NLRs), retinoic acid‐inducible gene (RIG)‐I‐like receptors (RLRs), and AIM2‐like receptors (ALRs). TLRs are the best‐characterized PPRs and are essential modulators of the innate immune response, as they survey both the intracellular and extracellular space. 9 The widespread cellular localization of TLRs confirms their central role in recognizing potential threats and, indeed, some receptors are able to initiate signaling cascades from either the plasma membrane or endosomes. Here, we provide an overview of the transduction pathways triggered by intracellular TLRs, with a particular focus on the signaling cascades elicited by TLR9 and the intracellular pathways of TLR4. We also discuss how TLR9 signaling may be involved in autoimmunity. TLRs are glycoproteins that consist of 3 domains: a transmembrane domain, an amino‐terminal ectodomain, and a cytoplasmic carboxy‐terminal Toll IL1‐1R homology (TIR) domain. 10 , 11 To activate downstream signaling pathways, TLRs recruit a variety of adaptor proteins, including the TIR‐containing adaptor protein (TIRAP), MyD88, the TIR domain‐containing adaptor inducing IFN‐β (TRIF), and the TRIF‐related adaptor molecule (TRAM). 12 Intracellular TLRs (TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, and TLR13) are expressed in the endoplasmic reticulum (ER), endosomes, multivesicular bodies, and lysosomes; their localization to endosomes and lysosomes, where self‐DNA is rarely present, is important to prevent autoimmunity and inappropriate immune responses. Intracellular TLRs recognize either nucleic acids (TLR3, TLR7, TLR8, TLR9, and TLR13) or microbial components (TLR11‐TLR12), both derived from the hydrolytic degradation of microorganisms in the endolysosomal compartment. 13 The ligand of TLR3 is double‐stranded RNA, such as that of HSV‐1, which causes encephalitis, 14 small interfering RNAs, 15 and self RNAs from damaged cells (e.g., RNA damaged by ultraviolet B irradiation). 16 Similarly, TLR7 in plasmacytoid dendritic cells (pDCs) recognizes viral single‐strande -Abstract Truncated-

TLR10 (CD290) Is a Regulator of Immune Responses in Human Plasmacytoid Dendritic Cells

TLR10 Is a Negative Regulator of Both MyD88-Dependent and -Independent TLR Signaling

TLR10: An intriguing Toll-like receptor with many unanswered questions

TLR10 and Its Unique Anti-Inflammatory Properties and Potential Use as a Target in Therapeutics

TLR10: Insights, controversies and potential utility as a therapeutic target

TLR2-dependent Activation of Β-Catenin Pathway in Dendritic Cells Induces Regulatory Responses and Attenuates Autoimmune Inflammation.

Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction.

Integrin CD11b Negatively Regulates TLR9-triggered Dendritic Cell Cross-Priming by Upregulating Microrna-146A.

Modulation of plasmacytoid dendritic cells response in inflammation and autoimmunity

Computational Discovery and Experimental Confirmation of TLR9 Receptor Antagonist Leads

Tlr Agonists Induce Regulatory Dendritic Cells To Recruit Th1 Cells Via Preferential Ip-10 Secretion And Inhibit Th1 Proliferation

Regulatory NLRs Control the RLR-Mediated Type I Interferon and Inflammatory Responses in Human Dendritic Cells

TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function

Tumor Progression Locus 2 Promotes Mouse Plasmacytoid Dendritic Cell Cytokine Secretion and Signaling

Lipopolysaccharide Attenuates CD40 Ligand-Induced Regulatory B10 Cell Expansion and IL-10 Production in Mouse Splenocytes

Identification of a TLR4- and TRIF-dependent activation program of dendritic cells.

TLR3-Dependent Activation of TLR2 Endogenous Ligands Via the MyD88 Signaling Pathway Augments the Innate Immune Response

Below the surface: The inner lives of TLR4 and TLR9

Treatment of Autoimmune Inflammation by a TLR7 Ligand Regulating the Innate Immune System

Recent progress in the development of Toll-like receptor (TLR) antagonists

Select Targeting of Intracellular Toll-interleukin-1 Receptor Resistance Domains for Protection Against Influenza-Induced Disease.